{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:49:55Z","timestamp":1793029795001,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1001\/jama.2021.4172","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T11:01:13Z","timestamp":1620126073000},"page":"1744","source":"Crossref","is-referenced-by-count":123,"title":["Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases"],"prefix":"10.1001","volume":"325","author":[{"given":"Silje Watterdal","family":"Syversen","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro L\u00f8vik","family":"Goll","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin Kaasen","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Sandanger","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Christoffer","family":"Olsen","sequence":"additional","affiliation":[{"name":"Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Elin","family":"Gehin","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David John","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe Kirkes\u00e6ther","family":"Brun","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf Anton","family":"Klaasen","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Normann","family":"Karlsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Stavanger University Hospital, Stavanger, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir","family":"Noraberg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital of Southern Norway Trust, Arendal, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Zettel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Betanien Hospital, Skien, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud Kristine Aga","family":"Ljos\u00e5","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u00c5lesund Hospital, \u00c5lesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Julsrud","family":"Haugen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u00d8stfold Hospital Trust, Moss, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Johan","family":"Nj\u00e5lla","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nordland Hospital Trust, Bod\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trude Jannecke","family":"Bruun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of North Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine Aglen","family":"Seeberg","sequence":"additional","affiliation":[{"name":"Departement of Gastroenterology, Vestfold Hospital Trust, T\u00f8nsberg, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Michelsen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldri Kveine","family":"Strand","sequence":"additional","affiliation":[{"name":"Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svanaug","family":"Skorpe","sequence":"additional","affiliation":[{"name":"Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Marianne","family":"Blomgren","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fonna Hospital Trust, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvill Hovde","family":"Bragnes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Vestre Viken Hospital Trust, Drammen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Kvikne","family":"Dotterud","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turid","family":"Thune","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Magnus","family":"Ystr\u00f8m","sequence":"additional","affiliation":[{"name":"Department of Medicine, Innlandet Hospital Trust, Elverum, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roald","family":"Torp","sequence":"additional","affiliation":[{"name":"Department of Medicine, Innlandet Hospital Trust, Hamar, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Mielnik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rheumatology, and Physical Medicine, F\u00f8rde Hospital Trust, F\u00f8rde, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cato","family":"M\u00f8rk","sequence":"additional","affiliation":[{"name":"Akershus Dermatology Center, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Jahnsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9194","key":"joi210031r1","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"23","key":"joi210031r2","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"9317","key":"joi210031r3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"9271","key":"joi210031r4","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"joi210031r5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis.","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"issue":"6","key":"joi210031r6","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.jaip.2018.04.007","article-title":"The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders.","volume":"6","author":"Nencini","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"joi210031r7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/(ISSN)1529-0131","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"6","key":"joi210031r8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"joi210031r9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn\u2019s disease.","volume":"64","author":"Vande Casteele","year":"2","journal-title":"Gut"},{"issue":"8","key":"joi210031r10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.","volume":"15","author":"Papamichael","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"joi210031r11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/FTD.0000000000000421","article-title":"Current practice for therapeutic drug monitoring of biopharmaceuticals in rheumatoid arthritis.","volume":"39","author":"Medina","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"1","key":"joi210031r12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11938-019-00222-9","article-title":"Advances in therapeutic drug monitoring for small-molecule and biologic therapies in inflammatory bowel disease.","volume":"17","author":"Ma","year":"2019","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"1","key":"joi210031r13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/ibd\/izx023","article-title":"A survey study of gastroenterologists\u2019 attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease.","volume":"24","author":"Grossberg","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"joi210031r14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"joi210031r15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases.","volume":"153","author":"Vande Casteele","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"joi210031r16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease.","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"issue":"11","key":"joi210031r17","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/ecco-jcc\/jjy109","article-title":"Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis.","volume":"12","author":"Ricciuto","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"20","key":"joi210031r18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"joi210031r19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13063-019-3734-4","article-title":"Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).","volume":"21","author":"Syversen","year":"2020","journal-title":"Trials"},{"issue":"1","key":"joi210031r20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.v38:1","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"12","key":"joi210031r21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.v71.12","article-title":"2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures.","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"joi210031r22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"joi210031r23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"joi210031r24","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"8167","key":"joi210031r25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity.","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"4","key":"joi210031r26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity.","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"joi210031r27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid.","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"10086","key":"joi210031r28","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"joi210031r29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"joi210031r30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/bjd.2006.155.issue-4","article-title":"A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician\u2019s Global Assessment and Lattice System Physician\u2019s Global Assessment.","volume":"155","author":"Berth-Jones","year":"2006","journal-title":"Br J Dermatol"},{"issue":"10","key":"joi210031r31","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"joi210031r32","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease.","volume":"154","author":"D\u2019Haens","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"joi210031r33","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"joi210031r34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1874312901711010075","article-title":"Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients.","volume":"11","author":"Teresa","year":"2017","journal-title":"Open Rheumatol J"},{"issue":"3","key":"joi210031r35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00535-015-1102-z","article-title":"First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis\u2014results from a multicenter prospective randomized controlled trial and its post hoc analysis.","volume":"51","author":"Kobayashi","year":"2016","journal-title":"J Gastroenterol"},{"issue":"11","key":"joi210031r36","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"issue":"4","key":"joi210031r37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cgh.2015.11.014","article-title":"Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis.","volume":"14","author":"Papamichael","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"joi210031r38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/apt.14943","article-title":"Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn\u2019s disease patients: the usefulness of rapid testing.","volume":"48","author":"Verstockt","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"joi210031r39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study.","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"joi210031r40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus.","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"joi210031r41","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ajg.2014.106","article-title":"Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn\u2019s disease: post hoc analysis of a randomized controlled trial.","volume":"109","author":"Steenholdt","year":"2014","journal-title":"Am J Gastroenterol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2779549\/jama_syversen_2021_oi_210031_1620138016.88766.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T11:01:15Z","timestamp":1620126075000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2779549"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":41,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.4172","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}